880144-47-8

Upstream product

• 1092935-86-8 tert-butyl [(2Z,3R,6S)-6-(2,3-difluorophenyl)-2-({2-hydroxy-2-[1-(trifluoromethyl)cyclopropyl]ethyl}imino)azepan-3-yl]carbamate 
• 34404-30-3 N-(tert-butoxycarbonyl)-D-glutamic acid 1-benzyl ester 
• 880144-45-6 benzyl (5S)-N,N-bis(tert-butoxycarbonyl)-5-(2,3-difluorophenyl)-6-nitro-D-norleucinate 
• 784156-34-9 (R)-benzyl 2-[bis(tert-butoxycarbonyl)amino]-5-oxopentanoate 
• 784156-32-7 1-benzyl 5-methyl N,N-bis(tert-butoxycarbonyl)-D-glutamate 
• 784156-96-3 (5S)-N₂,N₂-bis(tert-butoxycarbonyl)-5-(2,3-difluorophenyl)-D-lysine 
• 784156-33-8 benzyl (2R,5E)-2-[bis(tert-butoxycarbonyl)amino]-6-nitrohex-5-enoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1092935-86-8 C₂₃H₃₀F₅N₃O₃ 
• 880144-46-7 tert-butyl (3R,6S)-6-(2,3-difluorophenyl)-2-thioxoazepan-3-ylcarbamate 
• 880144-61-6 2-amino-1-[1-(trifluoromethyl)cyclopropyl]ethanol 

Downstream Products

• 880144-58-1 C₁₈H₁₈F₅N₃ 

Relevant academic research and scientific papers

Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918

In our ongoing efforts to develop CGRP receptor antagonists for the treatment of migraine, we aimed to improve upon telecagepant by targeting a compound with a lower projected clinical dose. Imidazoazepanes were identified as potent caprolactam replacemen

CARBOXAMIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: I wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as mi